166 related articles for article (PubMed ID: 25492366)
1. [Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)].
Miyazaki A; Matsuo A; Iida A; Nishino N; Maeda K; Matsumoto Y; Orui S
Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):294-304. PubMed ID: 25492366
[No Abstract] [Full Text] [Related]
2. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
3. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
[TBL] [Abstract][Full Text] [Related]
4. [Hyperphosphatemia in dialysis: which binder?].
Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
6. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
[TBL] [Abstract][Full Text] [Related]
7. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
8. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].
Taniguchi K; Kakuta H; Tomura Y; Kaku S; Uchida W
Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):333-7. PubMed ID: 23749074
[No Abstract] [Full Text] [Related]
10. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
[TBL] [Abstract][Full Text] [Related]
11. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Greig SL; Plosker GL
Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
[TBL] [Abstract][Full Text] [Related]
13. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Ketteler M
Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
[TBL] [Abstract][Full Text] [Related]
14. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Floege J
Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
[TBL] [Abstract][Full Text] [Related]
15. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.
Xie D; Ye N; Li M
Int Urol Nephrol; 2018 May; 50(5):905-909. PubMed ID: 29294216
[TBL] [Abstract][Full Text] [Related]
16. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Bousher A; Al-Makki A; Sutton J; Shepler B
Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
[TBL] [Abstract][Full Text] [Related]
17. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
[TBL] [Abstract][Full Text] [Related]
18. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Pai AB; Jang SM; Wegrzyn N
Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
[TBL] [Abstract][Full Text] [Related]
19. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Locatelli F; Del Vecchio L
J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
